CDXS · Codexis, Inc.
$1.45
+0.02 (+1.40%)
At close · Aug 5
Market Cap
$131.35M
Shares
90.90M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$70.39M
+18.6%
FY2025
Net Income
-$43.97M
+32.6%
FY2025
Gross Margin
86.73%
+14.2pp
FY2025
Operating Margin
-59.3%
+39.3pp
FY2025
Diluted EPS
-$0.50
+43.8%
FY2025
Operating Cash Flow
-$19.38M
+60.8%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2026 (G) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $72M – $76M | $78.09M | $70.39MG | $59.35M | $70.14M | $138.59M | $104.75M | $69.06M | $68.46M | $60.59M | $50.02M | $48.84M | $41.8M | $35.31M | $31.92M | $88.3M | $123.87M | $107.1M | $82.91M | |
| — | $8.67M | $9.34M | $16.29M | $12.81M | $38.03M | $22.21M | $13.74M | $15.63M | $12.62M | $14.33M | $9.75M | $6.59M | $9.73M | $14.55M | $30.65M | $41.78M | $27.98M | $16.68M | |
| — | $69.42M | $61.05M | $43.06M | $57.33M | $100.56M | $82.55M | $55.31M | $52.83M | $47.97M | $35.7M | $39.08M | $35.22M | $25.58M | $17.37M | $57.65M | $82.08M | $79.12M | $66.23M | |
| — | — | 86.73% | 72.55% | 81.74% | 72.56% | 78.8% | 80.1% | 77.17% | 79.17% | 71.36% | 80.03% | 84.25% | 72.45% | 54.41% | 65.29% | 66.27% | 73.87% | 79.88% | |
| — | $50.81M | $52.31M | $46.26M | $58.89M | $80.1M | $55.92M | $44.19M | $33.87M | $29.98M | $29.66M | $22.23M | $20.67M | $22.76M | $31.61M | $56.79M | $61.05M | $52.41M | $54.73M | |
| — | $44.5M | $47.07M | $55.15M | $53.25M | $52.17M | $49.32M | $35.05M | $31.5M | $29.29M | $29.01M | $25.42M | $22.32M | $21.94M | $26.91M | $31.38M | $36.94M | $33.84M | $29.87M | |
| — | — | — | — | — | — | — | — | — | $0 | $0 | $2.81M | $3.37M | $3.37M | $3.37M | $3.51M | $3.72M | $1.06M | $957K | |
| — | — | $5.25M | $4.95M | $5.52M | $5.4M | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | — | $3.41M | $0 | $3.28M | $3.17M | $0 | $0 | — | — | — | — | — | — | $800K | $3.11M | — | — | — | |
| — | $78.12M | — | — | — | — | — | — | — | $71.89M | $72.99M | $57.4M | — | $54.42M | $73.07M | $118.81M | $139.77M | $114.23M | $101.27M | |
| — | $107.39M | $112.13M | $117.86M | $138.21M | $173.47M | $127.45M | $92.98M | $81.01M | $71.89M | $72.99M | $57.4M | $49.57M | $54.42M | $73.07M | — | — | — | — | |
| — | -$29.3M | -$41.74M | -$58.52M | -$68.07M | -$34.88M | -$22.7M | -$23.92M | -$12.55M | -$11.3M | -$22.97M | -$8.56M | -$7.77M | -$19.11M | -$41.15M | -$30.51M | -$15.91M | -$7.12M | -$18.37M | |
| — | — | -59.3% | -98.61% | -97.04% | -25.17% | -21.67% | -34.64% | -18.33% | -18.64% | -45.92% | -17.54% | -18.59% | -54.13% | -128.9% | -34.56% | -12.84% | -6.65% | -22.15% | |
| — | — | -$36.49M | -$53.57M | -$62.55M | -$29.48M | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | $13K | $0 | $0 | $529K | — | |
| — | $2.54M | $2.63M | $3.67M | $4.17M | $1.44M | $459K | $405K | $1.29M | $671K | $147K | $60K | $19K | $18K | $60K | $252K | $273K | $166K | $180K | |
| — | -$5.16M | -$4.81M | -$10.39M | -$12.27M | $124K | $1.15M | -$156K | -$656K | -$291K | -$92K | -$94K | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | $155K | — | — | |
| — | -$31.92M | -$43.93M | -$65.24M | -$76.17M | -$33.32M | -$21.09M | -$23.67M | -$11.92M | -$10.92M | -$22.92M | -$8.6M | -$7.92M | -$19.33M | -$41.39M | -$30.59M | -$16.31M | -$8.16M | -$20.22M | |
| — | $72K | $47K | $34K | $69K | $276K | $189K | $339K | $17K | -$37K | $81K | -$40K | -$338K | -$256K | -$87K | $270K | $241K | $384K | $66K | |
| — | -$31.99M | -$43.97M | -$65.28M | -$76.24M | -$33.59M | -$21.28M | -$24.01M | -$11.94M | -$10.88M | -$23M | -$8.56M | -$7.58M | -$19.07M | -$41.3M | -$30.86M | -$16.55M | -$8.54M | -$20.29M | |
| — | — | -62.47% | -109.99% | -108.69% | -24.24% | -20.31% | -34.77% | -17.43% | -17.95% | -45.97% | -17.52% | -18.13% | -54.01% | -129.39% | -34.95% | -13.36% | -7.97% | -24.47% | |
| — | -$32.02M | -$44.02M | -$65.22M | -$76.24M | -$33.59M | — | — | -$11.94M | -$10.88M | -$23.47M | -$8.96M | -$7.03M | -$19.18M | -$41.2M | -$30.59M | -$16.92M | -$8.32M | -$20.68M | |
| USD/shares | — | — | -$0.50 | -$0.89 | -$1.12 | -$0.51 | -$0.33 | -$0.40 | -$0.21 | — | — | — | — | — | — | — | — | — | — |
| USD/shares | — | — | -$0.50 | -$0.89 | -$1.12 | -$0.51 | -$0.33 | -$0.40 | -$0.21 | — | — | — | — | — | — | — | — | — | — |
| shares | — | — | 87.14M | 73.41M | 68.13M | 65.34M | 64.57M | 59.36M | 56.53M | 52.21M | 46.23M | 40.63M | 39.44M | 38.21M | 38.23M | 36.77M | 35.67M | 24.6M | — |
| shares | — | — | 87.14M | 73.41M | 68.13M | 65.34M | 64.57M | 59.36M | 56.53M | 52.21M | 46.23M | 40.63M | 39.44M | 38.21M | 38.23M | 36.77M | 35.67M | 24.59M | — |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 4.24×
EV/EBIT
—
Peer median 47.68×
P/E (TTM)
—
Peer median 4.24×
Peer medians compare against the 302 similar-size Biotechnology companies (of 520 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|
| Core Segment | $126,612,000 | $90,515,000 | $48,106,000 | $58,156,000 | $47,073,000 | — |
| Biotherapeutics Segment | $11,978,000 | $14,239,000 | $20,950,000 | $10,302,000 | $13,521,000 | — |
| Novel Biotherapeutics | — | — | — | — | — | $7,691,000 |
| Performance Enzymes | — | — | — | — | — | $42,333,000 |
By Geography (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Americas | $43,537,000 | $21,278,000 | $13,733,000 | $17,000,000 | $23,481,000 | $24,352,000 | $13,039,000 | $15,370,000 |
| United States | $43,500,000 | $21,300,000 | $13,700,000 | $17,000,000 | $23,400,000 | — | — | — |
| Asia Pacific | $17,558,000 | $27,708,000 | $33,503,000 | $65,050,000 | $61,086,000 | $25,447,000 | $18,286,000 | — |
| China | $9,300,000 | $9,800,000 | $20,300,000 | $48,600,000 | $43,500,000 | — | — | — |
| EMEA | $9,292,000 | $10,359,000 | $22,907,000 | $56,540,000 | $20,187,000 | $19,257,000 | $37,133,000 | $22,361,000 |
| India | $5,700,000 | $7,300,000 | $5,700,000 | $8,800,000 | — | — | — | — |
| Switzerland | $4,200,000 | $3,400,000 | $11,100,000 | $9,200,000 | $10,100,000 | — | — | — |
| Ireland | $700,000 | $1,800,000 | $500,000 | $37,200,000 | $1,400,000 | — | — | — |
| Singapore | $400,000 | $6,200,000 | $2,400,000 | $3,200,000 | — | — | — | — |
| APAC | — | — | — | — | — | $25,447,000 | $18,286,000 | $22,863,000 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Research and Development Revenue | $44,359,000 | $22,559,000 | $27,237,000 | $21,914,000 | $34,097,000 | $38,836,000 | $38,993,000 | $35,004,000 |
| Product | $26,028,000 | $36,786,000 | $42,906,000 | $116,676,000 | $70,657,000 | — | — | — |
| Product Sales | — | — | — | — | — | $30,220,000 | $29,465,000 | $25,590,000 |
| Service | — | — | — | — | — | $38,836,000 | $38,993,000 | $35,004,000 |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|
| Core Segment | $46,361,000 | $33,061,000 | $3,844,000 | $14,682,000 | $7,991,000 | — |
| Biotherapeutics Segment | -$41,179,000 | -$18,735,000 | -$3,110,000 | -$5,198,000 | $2,565,000 | — |
| Novel Biotherapeutics | — | — | — | -$5,198,000 | $2,565,000 | -$4,416,000 |
| Performance Enzymes | — | — | — | $14,682,000 | $7,991,000 | $3,788,000 |
Operating Margin by Segment (%)
| Component | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|
| Core Segment | 36.6% | 36.5% | 8% | 25.2% | 17% | — |
| Biotherapeutics Segment | -343.8% | -131.6% | -14.8% | -50.5% | 19% | — |
| Novel Biotherapeutics | — | — | — | — | — | -57.4% |
| Performance Enzymes | — | — | — | — | — | 8.9% |
Key facts
CIK
1200375
CUSIP
192005106
13F (30d)
33 filings
32 filers
Visit website
Investor relations